RxDoctor Payments DataLook up a doctor →

Santiago Mazuera Mesia, MD

Neurology · Baltimore, MDNPI 1235484056

Payments from drug & device makers

$257,598in general payments, 2019–2025

Across 1,009 payments — averaging $255.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$201K
  • Biohaven Pharmaceuticals, Inc.$30K
  • Biohaven Pharmaceutical Holding Company Ltd.$15K
  • Amgen$5K
  • Impel Pharmaceuticals Inc.$1K
  • Teva Pharmaceuticals USA, Inc.$869
  • plus $5K from 43 others

What the payments were for

  • Consulting fees$6,9633%
  • Speaking & faculty fees$227,24688%
  • Travel & lodging$6,3712%
  • Food & beverage$16,9617%
  • Education$580%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$257,598 in reported general payments places this provider in the 90th percentile of 442 neurology providers in Maryland.

See all neurology providers in Maryland

Medicare billing

Part B allowed, 2024
$314,600
Medicare patients
168
Services billed
41,644

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UbrelvyUbrogepant57$73,974
Nurtec OdtRimegepant Sulfate38$44,892
QuliptaAtogepant29$32,457
Emgality PenGalcanezumab-Gnlm20$14,542
Aimovig AutoinjectorErenumab-Aooe19$13,572
Ajovy AutoinjectorFremanezumab-Vfrm11$10,739
Ajovy SyringeFremanezumab-Vfrm13$9,115
Sumatriptan Succinate32$1,072
Gabapentin40$596
Topiramate24$194
RizatriptanRizatriptan Benzoate12$161
Diclofenac Potassium19$112
Ondansetron OdtOndansetron16$49

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta$200,909$106,43186 claims
PfizerNurtec Odt$317$44,89238 claims
Upsher-smith Laboratories LLCTopiramate$108$19424 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 442 neurology providers in Maryland.

Other neurology in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →